No Data
No Data
Shoei Pharmaceuticals - Differences between actual results and financial estimates for the second quarter of the fiscal year ending March 2025, and revision of full-year financial estimates.
Showa Yakuhin <3537> announced on the 8th that it has revised the consolidated financial estimates and actual results for the second quarter of the fiscal year ending March 2025 (April-September 2024), as well as the revised consolidated financial estimates for the full year ending March 2025 (April 2024-March 2025). The actual revenue for the second quarter of the fiscal year ending March 2025 (interim period) was 12.286 billion yen, an increase of 9.5% compared to the previous forecast, operating profit increased by 77.1% to 0.308 billion yen, ordinary profit increased by 60.3% to 0.407 billion yen, attributable to the parent company shareholder.
Shoei Yakuhin: Semi-annual report - 65th period (2024/04/01-2025/03/31)
Shoei Yakuhin: Notice regarding differences between consolidated earnings forecasts and actual results for the second quarter (interim period) of the fiscal year ending March 31, 2025 and revisions to the full-year consolidated earnings for...
Shoei Yakuhin: Summary of financial results for the 2nd quarter (interim period) for the fiscal year ending March 31, 2025 [Japanese GAAP] (consolidated)
Morinaga Milk, mcdonald's, Toyo Suisan, Eisai (8th) (1429-5463)
※Please note that the above calendar is tentative and subject to change based on the company's convenience. --------------------------------------- November 8th (Fri) <1429> Japan Aqua <1435> RoboHome <143A> Ishin <1450> Tanaka Construction Industry <1451> KHC <1518> Mitsui Matsushima HD <151A> Dai <167A> Ryo
Showa Koei Pharmaceuticals - 1Q revenue increase, double-digit profit increase, and the main chemical business is progressing smoothly.
Shoei Yakuhin <3537> announced its consolidated financial results for the first quarter of the 2025 fiscal year (April to June 24). Sales revenue increased by 7.2% to 5.973 billion yen compared to the same period last year, operating profit increased by 38.7% to 0.136 billion yen, ordinary profit increased by 35.5% to 0.173 billion yen, and net profit attributable to shareholders of the parent company increased by 36.7% to 0.116 billion yen. The chemical business' sales revenue increased by 7.5% to 5.459 billion yen compared to the same period last year, with a segment profit of 0.152 billion yen, up 25.5%.
No Data
No Data